Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Northwest Biotherapeutics (NWBO) Operating Income: 2010-2024

Historic Operating Income for Northwest Biotherapeutics (NWBO) over the last 15 years, with Dec 2024 value amounting to -$66.5 million.

  • Northwest Biotherapeutics' Operating Income rose 3.25% to -$14.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$64.9 million, marking a year-over-year decrease of 2.78%. This contributed to the annual value of -$66.5 million for FY2024, which is 19.82% down from last year.
  • Per Northwest Biotherapeutics' latest filing, its Operating Income stood at -$66.5 million for FY2024, which was down 19.82% from -$55.5 million recorded in FY2023.
  • Over the past 5 years, Northwest Biotherapeutics' Operating Income peaked at -$52.7 million during FY2021, and registered a low of -$86.6 million during FY2020.
  • Its 3-year average for Operating Income is -$63.1 million, with a median of -$66.5 million in 2024.
  • Per our database at Business Quant, Northwest Biotherapeutics' Operating Income slumped by 209.54% in 2020 and then soared by 39.15% in 2021.
  • Yearly analysis of 5 years shows Northwest Biotherapeutics' Operating Income stood at -$86.6 million in 2020, then skyrocketed by 39.15% to -$52.7 million in 2021, then dropped by 27.47% to -$67.2 million in 2022, then rose by 17.38% to -$55.5 million in 2023, then fell by 19.82% to -$66.5 million in 2024.